Exploring the in situ expression of vascular endothelial growth factor and endoglin in pemphigus foliaceus variants and pemphigus vulgaris
| Autor: | Valeria Aoki, Claudia Giuli Santi, David T. Miyamoto, Ana Beatriz Toledo Dias, Miguel N. Burnier, Jose Joao Mansure, Celina W. Maruta, Pablo Zoroquiain |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Adult
Male Vascular Endothelial Growth Factor A 0301 basic medicine Angiogenesis Erythroderma Dermatology 030207 dermatology & venereal diseases 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Predictive Value of Tests Reference Values Psoriasis medicine Humans Pemphigus foliaceus Aged Retrospective Studies Tissue Embedding business.industry Biopsy Needle Pemphigus vulgaris Endoglin Middle Aged Prognosis medicine.disease Immunohistochemistry Vascular endothelial growth factor 030104 developmental biology Infectious Diseases chemistry Desmoglein 1 Case-Control Studies Disease Progression Cancer research Female business Biomarkers Dermatitis Exfoliative Pemphigus |
| Zdroj: | Journal of the European Academy of Dermatology and Venereology. 32:1954-1958 |
| ISSN: | 1468-3083 0926-9959 |
| DOI: | 10.1111/jdv.14903 |
| Popis: | Background Erythroderma is a severe manifestation of pemphigus foliaceus (PF), a blistering disease mediated by IgG autoantibodies against desmoglein 1. Increasing evidence supports the contribution of angiogenic mediators in the pathogenesis of erythroderma. Objective To evaluate the in situ expression of vascular endothelial growth factor (VEGF) and endoglin in patients with PF with erythroderma. Methods Formalin-fixed paraffin-embedded skin samples obtained from patients with erythrodermic PF (n = 19; 12 patients with endemic PF), non-erythrodermic PF (n = 17), pemphigus vulgaris (PV; n = 10), psoriasis (n = 10) and healthy individuals (HI; n = 10) were processed in an automated immunohistochemistry platform utilizing anti-VEGF and anti-endoglin as primary antibodies. Reactivity was evaluated both manually (0 = negative; 1+ = mild; 2+ = intense) and through an automated microvessel analysis algorithm. Results Vascular endothelial growth factor expression in erythrodermic PF was higher than in non-erythrodermic PF (P = 0.034) and in HI (P = 0.004), and similar to psoriasis (P = 0.667) and PV (P = 0.667). In non-erythrodermic PF, VEGF positivity was similar to HI (P = 0.247), and lower than psoriasis (P = 0.049) and PV (P = 0.049). Both erythrodermic and non-erythrodermic PF presented similar endoglin expression (P = 0.700). In addition, endoglin positivity during erythrodermic PF was similar to psoriasis (P = 0.133) and lower than PV (P = 0.0009). Increased expression of in situVEGF suggests that healing processes are triggered in response to tissue damage led by autoantibodies in PF, especially during erythroderma. Reduced endoglin positivity suggests that an unbalanced angiogenesis may occur during erythrodermic PF. Further studies may help to confirm if the regulation of VEGF and endoglin expression in patients with PF can contribute to control the healing process and enable disease remission. Conclusion Overexpression of VEGF in erythrodermic PF as well as in PV and psoriasis points out a dysregulated repair process in severe forms of these diseases and suggests VEGF and endoglin could act as prognostic markers and future therapeutic targets to enable proper healing in PF. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text